134 related articles for article (PubMed ID: 34728553)
1. RKIP Induction Promotes Tumor Differentiation via SOX2 Degradation in NF2-Deficient Conditions.
Cho JH; Park S; Kim S; Kang SM; Woo TG; Yoon MH; Lee H; Jeong M; Park YH; Kim H; Han YT; Suh YG; Kim BH; Kwon Y; Yun H; Park BJ
Mol Cancer Res; 2022 Mar; 20(3):412-424. PubMed ID: 34728553
[TBL] [Abstract][Full Text] [Related]
2. Loss of NF2 Induces TGFβ Receptor 1-mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome.
Cho JH; Oh AY; Park S; Kang SM; Yoon MH; Woo TG; Hong SD; Hwang J; Ha NC; Lee HY; Park BJ
Mol Cancer Ther; 2018 Nov; 17(11):2271-2284. PubMed ID: 30135214
[TBL] [Abstract][Full Text] [Related]
3. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
[TBL] [Abstract][Full Text] [Related]
4. Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.
Doddrell RD; Dun XP; Shivane A; Feltri ML; Wrabetz L; Wegner M; Sock E; Hanemann CO; Parkinson DB
Brain; 2013 Feb; 136(Pt 2):549-63. PubMed ID: 23413263
[TBL] [Abstract][Full Text] [Related]
5. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
6. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
8. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
9. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.
Chiasson-MacKenzie C; Vitte J; Liu CH; Wright EA; Flynn EA; Stott SL; Giovannini M; McClatchey AI
Nat Commun; 2023 Mar; 14(1):1559. PubMed ID: 36944680
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
[TBL] [Abstract][Full Text] [Related]
11. Cellular prion protein (PrP
Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
[TBL] [Abstract][Full Text] [Related]
12. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.
Gehlhausen JR; Hawley E; Wahle BM; He Y; Edwards D; Rhodes SD; Lajiness JD; Staser K; Chen S; Yang X; Yuan J; Li X; Jiang L; Smith A; Bessler W; Sandusky G; Stemmer-Rachamimov A; Stuhlmiller TJ; Angus SP; Johnson GL; Nalepa G; Yates CW; Wade Clapp D; Park SJ
Hum Mol Genet; 2019 Feb; 28(4):572-583. PubMed ID: 30335132
[TBL] [Abstract][Full Text] [Related]
13. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
[TBL] [Abstract][Full Text] [Related]
14. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.
Schulze KM; Hanemann CO; Müller HW; Hanenberg H
Hum Mol Genet; 2002 Jan; 11(1):69-76. PubMed ID: 11773000
[TBL] [Abstract][Full Text] [Related]
15. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
16. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
[TBL] [Abstract][Full Text] [Related]
18. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
[TBL] [Abstract][Full Text] [Related]
19. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
20. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.
Lepont P; Stickney JT; Foster LA; Meng JJ; Hennigan RF; Ip W
Mutat Res; 2008 Jan; 637(1-2):142-51. PubMed ID: 17868749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
